RT Journal Article
SR Electronic
T1 A systems approach to inflammation identifies therapeutic targets in SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.23.20110916
DO 10.1101/2020.05.23.20110916
A1 van de Veerdonk, Frank L.
A1 Janssen, Nico A.F.
A1 Grondman, Inge
A1 de Nooijer, Aline H.
A1 Koeken, Valerie A.C.M.
A1 Matzaraki, Vasiliki
A1 Boahen, Collins K.
A1 Kumar, Vinod
A1 Kox, Matthijs
A1 Koenen, Hans J.P.M.
A1 Smeets, Ruben L.
A1 Joosten, Irma
A1 Brüggemann, Roger J.M.
A1 Kouijzer, Ilse J.E.
A1 van der Hoeven, Hans G.
A1 Schouten, Jeroen A.
A1 Frenzel, Tim
A1 Reijers, Monique
A1 Hoefsloot, Wouter
A1 Dofferhoff, Anton S.M.
A1 Kerckhoffs, Angèle P.M.
A1 Blaauw, Marc J.T.
A1 Veerman, Karin
A1 Maas, Coen
A1 Schoneveld, Arjan H.
A1 Hoefer, Imo E.
A1 Derde, Lennie P.G.
A1 Willems, Loek
A1 Toonen, Erik
A1 van Deuren, Marcel
A1 van der Meer, Emeritus Jos W.M.
A1 van Crevel, Reinout
A1 Giamarellos-Bourboulis, Evangelos J.
A1 Joosten, Leo A.B.
A1 van den Heuvel, Michel M.
A1 Hoogerwerf, Jacobien
A1 de Mast, Quirijn
A1 Pickkers, Peter
A1 Netea, Mihai G.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/24/2020.05.23.20110916.abstract
AB Background Infection with SARS-CoV-2 manifests itself as a mild respiratory tract infection in the majority of individuals, which progresses to a severe pneumonia and acute respiratory distress syndrome (ARDS) in 10-15% of patients. Inflammation plays a crucial role in the pathogenesis of ARDS, with immune dysregulation in severe COVID-19 leading to a hyperinflammatory response. A comprehensive understanding of the inflammatory process in COVID-19 is lacking.Methods In this prospective, multicenter observational study, patients with PCR-proven or clinically presumed COVID-19 admitted to the intensive care unit (ICU) or clinical wards were included. Demographic and clinical data were obtained and plasma was serially collected. Concentrations of IL-6, TNF-α, complement components C3a, C3c and the terminal complement complex (TCC) were determined in plasma by ELISA. Additionally, 269 circulating biomarkers were assessed using targeted proteomics. Results were compared between ICU and non ICU patients.Findings A total of 119 (38 ICU and 91 non ICU) patients were included. IL-6 plasma concentrations were elevated in COVID-19 (ICU vs. non ICU, median 174.5 pg/ml [IQR 94.5-376.3] vs. 40.0 pg/ml [16.5-81.0]), whereas TNF-α concentrations were relatively low and not different between ICU and non ICU patients (median 24.0 pg/ml [IQR 16.5-33.5] and 21.5 pg/ml [IQR 16.0-33.5], respectively). C3a and terminal complement complex (TCC) concentrations were significantly higher in ICU vs. non ICU patients (median 556.0 ng/ml [IQR 333.3-712.5]) vs. 266.5 ng/ml [IQR 191.5-384.0] for C3a and 4506 mAU/ml [IQR 3661-6595] vs. 3582 mAU/ml [IQR 2947-4300] for TCC) on the first day of blood sampling. Targeted proteomics demonstrated that IL-6 (logFC 2.2), several chemokines and hepatocyte growth factor (logFC 1.4) were significantly upregulated in ICU vs. non ICU patients. In contrast, stem cell factor was significantly downregulated (logFC −1.3) in ICU vs. non ICU patients, as were DPP4 (logFC −0.4) and protein C inhibitor (log FC −1.0), the latter two factors also being involved in the regulation of the kinin-kallikrein pathway. Unsupervised clustering pointed towards a homogeneous pathogenetic mechanism in the majority of patients infected with SARS-CoV-2, with patient clustering mainly based on disease severity.Interpretation We identified important pathways involved in dysregulation of inflammation in patients with severe COVID-19, including the IL-6, complement system and kinin-kallikrein pathways. Our findings may aid the development of new approaches to host-directed therapy.Funding Vidi grant (F.L.v.d.V.) and Spinoza grant (M.G.N.) from the Netherlands Organization for Scientific Research, and ERC Advanced Grant (#833247 to M.G.N.).Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ET and LW are employees of Hycult Biotech. The other authors declare no competing interests. Funding StatementFLvdV is a recipient of a Vidi grant from the Netherlands Organization for Scientific Research. MGN is a recipient of a Spinoza grant from the Netherlands Organization for Scientific Research and of an ERC Advanced Grant (#833247).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The performance of this study and its study protocols (CMO dossier numbers 2020-6344 and 2016-2923) have been reviewed and approved by the Research Ethics Committee Arnhem-Nijmegen.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available for review upon request.